AGAryan Gajjar

Aryan Gajjar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aryan Gajjar has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Age-Dependent Remodeling of Parvalbumin Interneuron-Associated Networks Alters Corticospinal Output in the Motor Cortex

    by Xiaofei Wei, Istvan Mody, Yixin Wu, Aryan Gajjar, Gurnoor Singh, Vignesh Neerathalingam, Adeline Sun, Ruyi Huang, Sandra M. Holley, Daniel C. Lu

    The primary motor cortex (M1) controls voluntary movements through coordinated interactions between excitatory pyramidal neurons and inhibitory parvalbumin-expressing interneurons (PV-INs). Although PV-INs are critical to regulating motor output and motor coordination, their role in age-related motor decline remains unclear. Here, we investigated how aging alters PV-IN-associated regulation of corticospinal tract (CST) output in mice. Aged mice (14–24 months) exhibited selective motor impairments, including deficits in balance and hindlimb-supported performance, while general locomotor activity remained largely preserved. We combined optogenetics, ex vivo electrophysiology, retrograde tracing, and in vivo electromyographic (EMG) recordings. In aged M1 slices, optogenetic stimulation of the PV-IN-targeted network produced small extracellular-like voltage deflections recorded with a loose-apposed, non-sealed pipette configuration. These responses persisted during GABAA receptor blockade but were abolished by DNQX and APV, indicating engagement of an ionotropic glutamate receptor-dependent network mechanism. Whole-cell recordings obtained in separate experiments demonstrated that conventional inhibitory PV-IN-to-pyramidal transmission remained detectable during repetitive stimulation. In vivo, PV-IN activation increased M1-evoked hindlimb EMG responses in aged mice but had little effect in young animals. Together, these findings identify an age-dependent reorganization of PV-IN-associated motor-cortical network function that alters the recruitment of glutamatergic mechanisms and corticospinal motor output. The present data do not establish the precise synaptic topology of this network response or whether the reorganization is compensatory or maladaptive.

  • Open Access

    Functional Remodeling of Parvalbumin Interneurons Enhances Corticospinal Output in the Aged Motor Cortex

    by Xiaofei Wei, Istvan Mody, Yixin Wu, Aryan Gajjar, Gurnoor Singh, Vignesh Neerathalingam, Adeline Luojia Sun, Ruyi Huang, Sandra M Holley, Daniel C. Lu

    The primary motor cortex (M1) controls voluntary movements through the coordinated interactions between excitatory pyramidal neurons (Pyr) and inhibitory parvalbumin-expressing interneurons (PV-INs). Although PV-INs are critical for regulating motor output and motor coordination, their role in age-related motor decline remains unclear. Here, we investigated how aging alters PV-INs modulation of corticospinal tract (CST) in mice. Aged mice (>14 Months) exhibited significant motor impairments, including deficits in balance and coordination in the balance beam and rope-pulling tasks, while general locomotor activity remained largely preserved. To determine whether these deficits were associated with altered motor cortical circuitry, we combined optogenetics, ex-vivo electrophysiology, and in-vivo electromyographic (eEMG) recordings. Optogenetic activation of PV-INs in aged M1 slices elicited glutamate receptor-dependent depolarizing postsynaptic potentials in layer V pyramidal neurons, indicating recruitment of a glutamate-dependent excitatory circuit. Notably, inhibitory transmission from PV-INs to pyramidal neurons remained intact, suggesting functional remodeling rather than loss of inhibitory connectivity. In vivo, optogenetic activation of PV-INs significantly enhanced CST-mediated hindlimb eEMG responses in aged mice but had little effect in young animals, demonstrating an age-dependent change in PV-IN regulation of motor output. Together, these findings reveal a previously unrecognized form of age-related circuit plasticity in the motor cortex. We propose that PV-INs undergo functional remodeling during aging, preserving inhibitory signaling while enhancing the recruitment of excitatory network mechanisms that facilitate CST output. This adaptive reorganization may represent a compensatory response to age-related motor circuit dysfunction and identifies inhibitory microcircuits as potential therapeutic targets for improving motor function in the aging brain.

  • Open Access

    Cardiovascular Risk Stratification and Surveillance in Cardio-Oncology: Mechanistic Foundations and Future Directions

    by Aryan Gajjar, Syed Asfand Yar Shah, Amani Gajjar, Krishna C. Allam, Bryce Beech, Andrew Pfaff, Claiborne Brochu, Sourbha Dani, Sanju Ganatra

    Cardio-oncology has emerged as a critical discipline in modern medicine due to the growing population of cancer survivors and the increasing recognition of cardiovascular disease as a major cause of morbidity and mortality in this population. While there have been significant advances in chemotherapy such as advances in chemotherapy, targeted therapies, immunotherapies, and radiation therapy, these treatments are linked to a wide range of cardiovascular toxicities such as myocarditis, arrhythmias, and progressive fibrotic remodeling. These toxicities tend to be caused by interrelated and multifactorial cellular processes including endothelial damage, immunological dysregulation and mitochondrial dysfunction. Therefore, early diagnosis of subclinical harm using multimodal surveillance strategies integrating clinical risk assessment, specialized clinical imaging, and circulating biomarkers has replaced reactive care of overt cardiotoxicity in modern cardio-oncology. Echocardiographic techniques such as longitudinal strain, with the help of biomarker-guided surveillance of natriuretic peptides and cardiac troponins, have made the early detection of cardiac dysfunction more effective. However, the current prediction risk models are still constrained and limited by their dependence on static clinical variables and their partial integration of biological mechanisms. This review examines the current methods for risk stratification and surveillance throughout the cancer care continuum, including baseline assessment, monitoring during active therapy, and long-term survivorship surveillance. Future approaches for tailored cardiovascular care are also highlighted, including new advances in precision cardio-oncology such as multi-omics profiling, molecular biomarkers, artificial intelligence, and mechanism-guided preventative strategies. Therefore, advancing biologically informed and risk-adapted monitoring frameworks may enhance early diagnosis, maximize cardioprotective measures, and lower long-term cardiovascular consequences.

  • Open Access

    SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiovascular–Kidney–Metabolic Syndrome

    by Aryan Gajjar, Arvind Kumar Raju, Amani Gajjar, Mythili Menon, Syed Asfand Yar Shah, Sourbha Dani, Andrew Weinberg

    Cardiovascular–Kidney–Metabolic (CKM) syndrome symbolizes a single pathophysiologic entity including obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. These conditions altogether accelerate adverse outcomes when they coexist. Recent evidence has shown that the function of glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium–glucose cotransporter-2 inhibitors (SGLT2i) alleviate stress on multiple organs. SGLT2i has been demonstrated to benefit heart failure, hemodynamic regulation, and renal protection while GLP-1RA on the other hand has been shown to demonstrate a strong impact on glycemic management, weight loss, and atherosclerotic cardiovascular disease. This review will aim to understand and evaluate the mechanistic rationalization, clinical evidence, and the potential therapeutic treatment of SGLT2 inhibitors and GLP-1 receptor agonists to treat individuals who have CKM syndrome. This analysis also assesses whether combination therapy can be a synergistic approach that may benefit patients but is still underutilized because of the lack of clear guidelines, the associated costs, and disparities in accessibility. Therefore, in this review, we will be discussing the combination therapy’s additive and synergistic effects, current recommendations and clinical evidence, and mechanistic insights of these GLT2 inhibitors and GLP-1 receptor agonists in CKM syndrome patients. Overall, early and combination usage of GLP-1RA and SGLT2i may be essential to demonstrating a significant shift in modern cardiometabolic therapy toward patient-centered care.


  • Open Access

    Hypoabsorption in Bariatric Surgery: Is the Benefit Worth the Risk?

    by Tala Abedalqader, Noura Jawhar, Aryan Gajjar, Ray Portela, Gerardo Perrotta, Nour El Ghazal, Simon J. Laplante, Omar M. Ghanem

    Metabolic and bariatric surgery has been well described in the existing literature to be an effective and safe modality for weight loss in patients with obesity. Recently, hypoabsorptive procedures such as one-anastomosis gastric bypass (OAGB), biliopancreatic diversion with duodenal switch (BPD-DS), and single-anastomosis duodenoileostomy with sleeve (SADI-S) have gained traction, particularly among patients with severe obesity. These procedures combine restrictive and hypoabsorptive mechanisms, resulting in significant and sustainable weight loss, especially in those with severe obesity and associated comorbidities. However, the risk of malnutrition and nutritional deficiency following these procedures has been a deterrent for surgeons in their adoption. This review evaluates the existing literature on the safety, efficacy, and long-term outcomes of OAGB, BPD-DS, and SADI-S. While these hypoabsorptive procedures represent highly effective options for treating obesity, the associated nutritional complications necessitate the need for long-term follow-up and supplementation and highlight the need for careful patient selection.


  • Long-Term Safety and Efficacy Profile of Bariatric Surgery in Patients Classified with ASA IV Status

    by Noura Jawhar, Kamal Abi Mosleh, Kalpana Muthusamy, Aryan Gajjar, Richard S. Betancourt, Simon J. Laplante, Michael L. Kendrick, Omar M. Ghanem

    Introduction Metabolic and bariatric surgery (MBS) is a safe and effective treatment option to reduce weight and manage obesity-related medical conditions in patients with obesity. However, due to limited data, there is uncertainty regarding the short-, mid-, and long-term safety and efficacy profile of MBS in patients with a preoperative ASA IV status. Methods A single-center retrospective cohort study was performed on patients with ASA IV status who underwent sleeve gastrectomy (SG), Roux-en-Y gastric bypass (RYGB), or biliopancreatic diversion with duodenal switch (BPD-DS) between 2008 and 2020. Data collected included operative details; postoperative complications at 30 days, 90 days, and beyond 90 days; BMI changes; and resolution of obesity-related comorbidities at 0, 6, 12, 24, 48, and 60 months postoperatively. Results Among 131 ASA class IV patients, 43 patients underwent SG (32.8%), 66 patients underwent RYGB (50.4%), and 22 patients underwent BPD-DS (16.8%). The greatest %TWL occurred in the BPD-DS cohort (39.5%) at 24 months post-op followed by the RYGB (32.5%) and SG (20.7%) cohorts (p < 0.001). The overall major 30-day complication rate was 8.4% (n = 11/131), while the overall major 90-day complication rate within the cohort was 6.9% (n = 9/131). The overall major late (> 90 days) complication rate was found to be 14.5% (n = 19/131). Conclusions Our study demonstrated that MBS is relatively safe and effective in ASA IV patients in the short-, mid-, and long-term. Accordingly, careful procedure selection is required in this patient population. Further long-term studies are needed to support our findings.


  • Open Access

    Advances in Metabolic Bariatric Surgeries and Endoscopic Therapies: A Comprehensive Narrative Review of Diabetes Remission Outcomes

    by Wissam Ghusn, Jana Zeineddine, Richard S. Betancourt, Aryan Gajjar, Wah Yang, Andrew G. Robertson, Omar M. Ghanem

    Background and Objectives: Type 2 diabetes (T2D), closely associated with obesity, contributes to increased morbidity and mortality due to complications such as cardiometabolic disease. This review aims to evaluate the effectiveness of metabolic and bariatric surgeries (MBS) and endoscopic bariatric therapies (EBTs) in achieving diabetes remission and to examine key predictors influencing remission outcomes. Materials and Methods: This review synthesizes data from studies on MBS and EBT outcomes, focusing on predictors for diabetes remission such as preoperative insulin use, diabetes duration, HbA1c, and C-peptide levels. Additionally, predictive scoring systems, including the Individualized Metabolic Surgery (IMS), DiaRem, Advanced-DiaRem, ABCD, and Robert et al. scores, were analyzed for their utility in forecasting remission likelihood. Results: Key predictors of T2D remission include shorter diabetes duration, lower HbA1c, and higher C-peptide levels, while prolonged insulin use, and higher insulin doses are associated with lower remission rates. Scoring models like IMS and DiaRem demonstrate that lower scores correlate with a higher likelihood of remission, especially for procedures such as Roux-En-Y gastric bypass (RYGB). RYGB generally shows higher remission rates compared to sleeve gastrectomy (SG), particularly among patients with mild disease severity, while EBTs like ESG and IGBs contribute 5–20% total weight loss (TWL) and moderate glycemic control improvements. Conclusions: Both MBS and EBTs are effective for T2D management, with predictive scoring models aiding in individualized patient selection to optimize remission outcomes. Further research to validate these predictive tools across diverse populations could enhance treatment planning for both surgical and endoscopic interventions.


  • Open Access

    Timing of anticoagulation for patients with atrial fibrillation after acute ischemic stroke: Systematic review and meta-analysis

    by Omar M. Al-Janabi, Anas Odeh, Aryan Gajjar, Avi Misra, Yamama M. Mahmood, Amira M. Taha, Rishabh Gupta, Sherief Ghozy, Alejandro A. Rabinstein, David F. Kallmes


  • Open Access

    Current Stroke Solutions Using Artificial Intelligence: A Review of the Literature

    by Omar M. Al-Janabi, Amro El Refaei, Tasnim Elgazzar, Yamama M. Mahmood, Danah Bakir, Aryan Gajjar, Aysha Alateya, Saroj Kumar Jha, Sherief Ghozy, David F. Kallmes, et al.

    Introduction: In recent years, artificial intelligence (AI) has emerged as a transformative tool for enhancing stroke diagnosis, aiding treatment decision making, and improving overall patient care. Leading AI-driven platforms such as RapidAI, Brainomix®, and Viz.ai have been developed to assist healthcare professionals in the swift and accurate assessment of stroke patients. Methods: Following the PRISMA guidelines, a comprehensive systematic review was conducted using PubMed, Embase, Web of Science, and Scopus. Characteristic descriptive measures were gathered as appropriate from all included studies, including the sensitivity, specificity, accuracy, and comparison of the available tools. Results: A total of 31 studies were included, of which 29 studies focused on detecting acute ischemic stroke (AIS) or large vessel occlusions (LVOs), and 2 studies focused on hemorrhagic strokes. The four main tools used were Viz.ai, RapidAI, Brainomix®, and deep learning modules. Conclusions: AI tools in the treatment of stroke have demonstrated usefulness for diagnosing different stroke types, providing high levels of accuracy and helping to make quicker and more precise clinical judgments.


  • Impact of D-dimer on the outcomes of endovascular thrombectomy for acute ischemic stroke: A systematic review and meta-analysis

    by Abdullah Reda, Sherief Ghozy, Mohamed Elfil, Eris Spirollari, Aryan Gajjar, Fawaz Al-Mufti

    Background: There has been growing data about the association between D-dimer levels and thrombectomy outcomes in acute ischemic stroke patients (AIS) with no cumulative evidence. This systematic review and meta-analysis aim to discuss and analyze the findings of the current studies to provide more robust evidence in this regard. Methods: A systematic search was conducted through PubMed, Web of Science, Embase, and Scopus to retrieve all relevant investigations. A meta-analysis was conducted, and the results were presented in odds ratio (ORs) for binary variables and ratio of means (ROM) for continuous variables, each accompanied by its respective 95% confidence intervals (CIs). Results: After searching and screening, 14 studies were included. The analysis showed that the low D-dimer group had significantly higher rates of favorable functional outcome (OR: 4.40; 95%CI: 2.65–7.30; p < 0.001, n = 3) and recanalization (OR: 4.13; 95%CI: 1.57–10.84; p = 0.004, n = 3) than the high one. The association between D-dimer levels and first-pass effect and re-occlusion risk was also demonstrated. Eventually, two studies also demonstrated a significant association between high D-dimer levels and deep venous thrombosis and symptomatic intracranial hemorrhage as post-thrombectomy complications. Conclusion: Current evidence indicates a significant association between D-dimer levels and post-thrombectomy outcomes in AIS patients. However, current data are remarkably heterogeneous, and additional comparative investigations are needed.